← Back to Patent Explorer
US5428015A Expired / Lapsed US ⏱️ 0.0 years remaining

Vasoactive intestinal polypeptide analogues and use thereof

Assignee: Sanwa Kagaku Kenkyusho Co Ltd
•
Filing: 1994-02-24
•
Granted: 1995-06-27
•
Expires: 2014-02-24
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Vasoactive intestinal polypeptide (VIP) analogues and use thereof are disclosed. The VIP analogues are shown by the formula of His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-X-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-Y wherein X is a residue of amino acid other than methionine (Met); and Y is homoserine, homoserine-lactone, amidized homoserine, a residue reacted homoserine-lactone with a primary alkyl amine having carbon atoms not exceeding 20, or an optional polypeptide chain and containing an amidized homoserine at C-terminal. Each of the VIP analogues is employed as an effective ingredient for various medicines and a hair tonic, and more particularly curing an asthma and impotence.

Inventors

  • 👤 Masayasu Kurono
  • 👤 Takahiko Mitani
  • 👤 Haruo Takahashi
  • 👤 Kiichi Sawai

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 15:29
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/57563; A; A61; A61K; A61K38/00

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 41 words
A vasoactive intestinal polypeptide (VIP) analogue selected from the group consisting of [L-Leu 17 ]-VIP-Hse, [L-Leu 17 ]-VIP-Hse-lactone, [L-Leu 17 ]-VIP-Hse-NH 2 , [L-Leu 17 ]-VIP-Hse-NH(CH 2 ) 9 CH 3 and [L-Leu 17 ]-VIP-Hse-NH(CH 2 ) 19 CH 3 .
Claim 2
Dependent Claim 41 words
A vasoactive intestinal polypeptide (VIP) analogue selected from the group consisting of [L-Leu 17 ]-VIP-Hse, [L-Leu 17 ]-VIP-Hse-lactone, [L-Leu 17 ]-VIP-Hse-NH 2 , [L-Leu 17 ]-VIP-Hse-NH(CH 2 ) 9 CH 3 and [L-Leu 17 ]-VIP-Hse-NH(CH 2 ) 19 CH 3 .
Claim 3
Dependent Claim 56 words
A pharmaceutical composition comprising an effective amount of a vasoactive intestinal polypeptide (VIP) analogue selected from the group consisting of [L-Leu 17 ]-VIP-Hse, [L-Leu 17 ]-VIP-Hse-lactone, [L-Leu 17 ]-VIP-Hse-NH 2 , [L-Leu 17 ]-VIP-Hse-NH(CH 2 ) 9 CH 3 and [L-Leu 17 ]-VIP-Hse-NH(CH 2 ) 19 CH 3 , in combination with a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim 56 words
A pharmaceutical composition comprising an effective amount of a vasoactive intestinal polypeptide (VIP) analogue selected from the group consisting of [L-Leu 17 ]-VIP-Hse, [L-Leu 17 ]-VIP-Hse-lactone, [L-Leu 17 ]-VIP-Hse-NH 2 , [L-Leu 17 ]-VIP-Hse-NH(CH 2 ) 9 CH 3 and [L-Leu 17 ]-VIP-Hse-NH(CH 2 ) 19 CH 3 , in combination with a pharmaceutically acceptable carrier.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-06-26 1998-12-26 1999-06-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-06-26 2002-12-26 2003-06-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-06-26 2006-12-26 2007-06-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag